Business Context and Reporting Period
Company: ARTIVION, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Artivion is a leader in manufacturing medical devices and implantable human tissues for cardiac and vascular surgery. The company operates two reportable segments: Medical Devices (aortic stent grafts, On-X heart valves, surgical sealants) and Preservation Services (cardiac and vascular tissue processing).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total Revenues | $125,757 | $112,972 | $242,094 | $211,950 |
| Gross Margin | $80,517 | $73,112 | $155,965 | $136,689 |
| Gross Margin % | 64% | 65% | 64% | 64% |
| Operating (Loss) Income | $(8,364) | $8,384 | $(2,577) | $10,529 |
| Net (Loss) Income | $(13,510) | $1,345 | $(12,093) | $840 |
| Diluted EPS | $(0.28) | $0.03 | $(0.25) | $0.02 |
| Cash and Equivalents (Balance Sheet) | $77,316 (as of June 30, 2026) | |||
| Total Debt (Principal) | $370,000 (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11% year-over-year (Q2) and 14% year-over-year (YTD). Growth was driven by aortic stent grafts (+16% Q2, +19% YTD) and On-X products (+19% Q2, +20% YTD). Constant currency revenue growth was 9% for Q2 and 10% YTD.
- Profitability Decline: The company reported a net loss of $13.5 million for Q2 2026 compared to net income of $1.3 million in Q2 2025. This shift from profit to loss was primarily due to significant non-recurring expenses.
- Acquisition Impact: The company acquired Endospan Ltd. in May 2026 for a total consideration of approximately $178.1 million. This resulted in $12.5 million in transaction costs (including $10.2 million in transaction bonuses) recognized in the first six months of 2026.
- Contingent Consideration: A $9.7 million fair value loss on contingent consideration related to the Ascyrus acquisition was recorded in the first six months of 2026, compared to a $0.2 million gain in the prior year period. This was driven by the FDA approval of the AMDS PMA in June 2026, triggering a $25 million milestone payment.
- Debt Structure: Total principal debt increased from $220 million to $370 million due to a $150 million draw on a New Delayed Draw Term Loan Facility to fund the Endospan acquisition.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes the revenue increase to volume growth in aortic stent grafts and On-X products, as well as favorable foreign exchange rates. The operating loss is attributed to acquisition-related costs and contingent consideration adjustments rather than core operational performance.
- Liquidity: As of June 30, 2026, the company held $77.3 million in cash and cash equivalents with $30.0 million of unused capacity under its revolving credit facility. Management believes existing cash and credit facilities are sufficient for the next 12 months.
- Regulatory Milestones: The FDA granted Premarket Approval (PMA) for the AMDS Hybrid Prosthesis in June 2026, enabling full commercial distribution in the US. This triggered a $25 million contingent payment to Ascyrus shareholders in July 2026.
- Risks and Contingencies:
- Geopolitical: The Endospan NEXUS products are manufactured in Israel; ongoing conflicts in the Middle East pose supply chain risks.
- Tax: The company is under examination by the German Federal Central Tax Office regarding intercompany financing arrangements, with a potential exposure of approximately €7 million if the authority prevails.
- Regulatory: Risks related to the transition to the EU Medical Device Regulation (MDR) and potential FDA reclassification of allograft heart valves to Class III devices.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost of integrating Endospan and the realization of anticipated synergies.
- Contingent Liabilities: Monitor the fair value of contingent consideration for Ascyrus and Endospan, which can significantly impact earnings based on revenue milestones and regulatory approvals.
- Debt Covenants: Confirm continued compliance with the total net leverage ratio covenant (maximum 5.75x) given the increased debt load from the Endospan acquisition.
- Regulatory Status: Track the commercial adoption of the AMDS following its June 2026 PMA approval and the status of the NEXUS family of products in the US market.
- German Tax Examination: Assess the potential financial impact of the ongoing German tax authority examination regarding intercompany financing.